CN116173168B - 一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法 - Google Patents
一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法 Download PDFInfo
- Publication number
- CN116173168B CN116173168B CN202211392938.3A CN202211392938A CN116173168B CN 116173168 B CN116173168 B CN 116173168B CN 202211392938 A CN202211392938 A CN 202211392938A CN 116173168 B CN116173168 B CN 116173168B
- Authority
- CN
- China
- Prior art keywords
- parts
- formula
- cold
- blood circulation
- dispelling wind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 37
- 230000036407 pain Effects 0.000 title claims abstract description 37
- 230000017531 blood circulation Effects 0.000 title claims abstract description 36
- 230000008961 swelling Effects 0.000 title claims abstract description 35
- 210000002435 tendon Anatomy 0.000 title claims abstract description 26
- 230000003213 activating effect Effects 0.000 title claims abstract description 25
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000002674 ointment Substances 0.000 title claims abstract description 12
- 238000013268 sustained release Methods 0.000 title claims description 10
- 239000012730 sustained-release form Substances 0.000 title claims description 10
- 239000003814 drug Substances 0.000 claims abstract description 47
- 238000002156 mixing Methods 0.000 claims abstract description 39
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims abstract description 24
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 21
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 14
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 14
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 14
- DZSVIVLGBJKQAP-UHFFFAOYSA-N 1-(2-methyl-5-propan-2-ylcyclohex-2-en-1-yl)propan-1-one Chemical compound CCC(=O)C1CC(C(C)C)CC=C1C DZSVIVLGBJKQAP-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 13
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 11
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 8
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 8
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 8
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 8
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 8
- 239000004863 Frankincense Substances 0.000 claims abstract description 8
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 8
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 8
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 8
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 8
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 8
- 235000008397 ginger Nutrition 0.000 claims abstract description 8
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 20
- 230000001737 promoting effect Effects 0.000 claims description 20
- 239000000600 sorbitol Substances 0.000 claims description 20
- 235000010356 sorbitol Nutrition 0.000 claims description 20
- 235000011187 glycerol Nutrition 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000008213 purified water Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 13
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 10
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 229940116229 borneol Drugs 0.000 claims description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 10
- 229940041616 menthol Drugs 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 9
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 claims description 9
- 239000009637 wintergreen oil Substances 0.000 claims description 9
- 239000005995 Aluminium silicate Substances 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 8
- 235000012211 aluminium silicate Nutrition 0.000 claims description 8
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 8
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 235000002906 tartaric acid Nutrition 0.000 claims description 8
- 239000011975 tartaric acid Substances 0.000 claims description 8
- 229910052782 aluminium Inorganic materials 0.000 claims description 7
- 238000005520 cutting process Methods 0.000 claims description 7
- 239000004745 nonwoven fabric Substances 0.000 claims description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 5
- 229960001777 castor oil Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 238000012372 quality testing Methods 0.000 claims description 3
- 241000758794 Asarum Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- OPRIWFSSXKQMPB-UHFFFAOYSA-N 2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid;sodium Chemical compound [Na].OS(=O)(=O)CC(C)(C)NC(=O)C=C OPRIWFSSXKQMPB-UHFFFAOYSA-N 0.000 claims 1
- 241000382455 Angelica sinensis Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 16
- 241000213006 Angelica dahurica Species 0.000 abstract description 12
- 241000227129 Aconitum Species 0.000 abstract description 6
- 241000489492 Arisaema Species 0.000 abstract description 6
- 235000017965 Asarum canadense Nutrition 0.000 abstract description 6
- 235000000385 Costus speciosus Nutrition 0.000 abstract description 6
- 241000606265 Valeriana jatamansi Species 0.000 abstract description 6
- 235000014687 Zingiber zerumbet Nutrition 0.000 abstract description 6
- 241001254604 Angelica pubescens Species 0.000 abstract description 5
- 240000009138 Curcuma zedoaria Species 0.000 abstract description 5
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 5
- 241000212322 Levisticum officinale Species 0.000 abstract description 5
- 241000329195 Sparganium erectum Species 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 5
- 239000001645 levisticum officinale Substances 0.000 abstract description 5
- 235000019509 white turmeric Nutrition 0.000 abstract description 5
- 240000005717 Dioscorea alata Species 0.000 abstract description 4
- 239000012467 final product Substances 0.000 abstract 1
- 235000017281 sodium acetate Nutrition 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 43
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 26
- 206010042674 Swelling Diseases 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 9
- 241000700198 Cavia Species 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 244000001632 Acorus gramineus Species 0.000 description 4
- 235000013073 Acorus gramineus Nutrition 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 241000034009 Lycopus Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical group O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法,它涉及缓释凝胶膏及其制备方法。本发明要解决现有凝胶膏存在缓释初期释放过快现象,较快的速度释放不利于人体吸收及恒定的药物浓度,无法取得较好的治疗效果的问题。祛风散寒、舒筋活血、消肿止痛缓释凝胶膏它由药剂和辅料组成,所述的药剂由没药、川芎、红花、黄柏、生川乌、生草乌、白芷、当归、干姜、三棱、莪术、乳香、独活、天南星、细辛、羌活、皮子药、泽兰、桃仁及石菖蒲组成;所述的辅料按质量份数包括羧甲纤维素钠、丙烯酰胺、2‑丙烯酰胺基‑2甲基丙磺酸钠及乙二胺四乙酸二钠;方法:制备浸膏浓缩液,分别混合配置配方一至六,最后制备膏体,并使用背衬层即覆盖膜。
Description
技术领域
本发明涉及缓释凝胶膏及其制备方法。
背景技术
巴布剂是20世纪70年代日本在泥罨剂基础上发展起来的,80年代发展到我国,90年代初我国就有了规模化生产。巴布剂又称凝胶膏剂,是一种由经皮肤贴敷方式用药,药物由皮肤吸收进入全身血液循环并达到有效血药浓度、实现疾病治疗或预防的一类制剂。其通常由背衬层、药膏层(基质+药物)、保护膜三部分组成。巴布剂的基质主要分为两类:一类为非交联型,以动植物胶为主;另一类为交联型,以高分子聚合物为主。非交联型基质不稳定,容易受到湿热的影响,而交联型基质形成了网状结构,提高了基质的内聚强度,从而提高了产品的稳定性、粘附性、透气性及生物利用度。
巴布剂与传统的橡胶膏和黑膏药相比具有明显的优势:
1、药物的吸收不受胃肠道因素的影响.减少用药的个体差异。
2、载药量大,传统的橡胶膏厚度一般为1.7g左右,巴布膏厚度约为7克左右,可以更好的承载中药提取浸膏,制成中药凝胶剂。
3、药物释放性好,保湿透气。采用亲水性高分子材料制成巴布膏基质,既能保持皮肤的湿润性又能使药物通过亲水基团经皮肤直接渗透到病灶部位,达到治疗的效果。
4、有适当的弹性和粘性,可反复粘贴,敷贴舒适,患者可以随时停药。传统橡胶膏和黑膏药采用弹性布,具有揭帖易粘带体毛,皮肤痛感,无法再次粘贴等缺点。
5、无刺激性过敏性、安全,无毒。巴布剂在制备过程中不适用汽油、铅丹等有机有毒物质,使用后无皮肤过敏反应。
6、采用交联型基质制成的巴布剂,稳定性更强,不受汗水干扰,载药量稳定,药物释放度稳定。
但现有凝胶膏存在缓释初期释放过快现象,较快的速度释放不利于人体吸收及恒定的药物浓度,无法取得较好的治疗效果。
发明内容
本发明要解决现有凝胶膏存在缓释初期释放过快现象,较快的速度释放不利于人体吸收及恒定的药物浓度,无法取得较好的治疗效果的问题,而提供一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法。
一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏,它由药剂和辅料组成;
所述的药剂按质量份数由25份~50份没药、35份~70份川芎、35份~70份红花、25份~50份黄柏、100份~200份生川乌、100份~200份生草乌、60份~120份白芷、60份~120份当归、50份~100份干姜、25份~50份三棱、25份~50份莪术、25份~50份乳香、25份~50份独活、100份~200份天南星、35份~70份细辛、25份~50份羌活、100份~200份皮子药、50份~100份泽兰、35份~70份桃仁及60份~120份石菖蒲组成;
所述的辅料按质量份数包括10份~100份羧甲纤维素钠、10份~50份丙烯酰胺、40份~150份2-丙烯酰胺基-2甲基丙磺酸钠及1份~15份乙二胺四乙酸二钠。
一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,它是按以下步骤进行的:
一、将药剂依次投入提取罐中,加入乙醇,回流提取3h~5h,提取液滤至贮药罐内,再向提取罐中加入乙醇,回流提取3h~5h,合并提取液,回收乙醇,浓缩提取液至在温度60℃~80℃的相对密度为1.20~1.30,得到浸膏浓缩液;
二、将浸膏浓缩液、冬青油、冰片、薄荷脑及蓖麻油混合均匀,得到配方一;
三、将第一份丙烯酰胺、第一份2-丙烯酰胺基-2甲基丙磺酸钠、第一份羧甲纤维素钠及第一份甘油混合均匀,得到配方二;
四、向山梨醇中加入纯化水,得到山梨醇水溶液,将高岭土与山梨醇水溶液混合均匀,得到配方三;
五、以纯化水为配方四;
六、将第二份丙烯酰胺、第二份2-丙烯酰胺基-2甲基丙磺酸钠、第二份羧甲纤维素钠、第二份甘油、甘羟铝及乙二胺四乙酸二钠混合均匀,得到配方五;
七、以酒石酸为配方六;
八、将配方一与配方二加入混合罐中混合,再依次加入配方三、配方四、配方五及配方六混合,然后静置并再混合,得到膏体;
九、将膏体转移到涂布切割机上,以医用无纺布为背衬层、以硅塑纸为覆盖膜,然后涂布切割,切割后静置,经质检包装后,即得祛风散寒、舒筋活血、消肿止痛缓释凝胶膏。
本发明的有益效果是:
本发明通过特定凝胶膏的选取及严格控制组分比例,使得凝胶膏起始时的突然释放被延缓,4h药物释放率小于25%,且10h的释放率小于80%,12h的释放率达到最大,释放率为98.9%,整体释放近似于线性,使药物以可控制的速度释放并被人体吸收,在血液中维持较为恒定的血药浓度,取得较好的治疗效果,风湿性关节炎患者治愈率达到98%,有效率达到100%。本发明的凝胶膏具有祛风散寒,活血消肿、解毒镇痛、活血祛瘀、消肿止痛、燥湿化痰、祛风解痉、行气活血、养血柔筋等功效。用于祛风散寒、舒筋活血、消肿止痛。
本发明用于一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法。
具体实施方式
具体实施方式一:本实施方式一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏,它由药剂和辅料组成;
所述的药剂按质量份数由25份~50份没药、35份~70份川芎、35份~70份红花、25份~50份黄柏、100份~200份生川乌、100份~200份生草乌、60份~120份白芷、60份~120份当归、50份~100份干姜、25份~50份三棱、25份~50份莪术、25份~50份乳香、25份~50份独活、100份~200份天南星、35份~70份细辛、25份~50份羌活、100份~200份皮子药、50份~100份泽兰、35份~70份桃仁及60份~120份石菖蒲组成;
所述的辅料按质量份数包括10份~100份羧甲纤维素钠、10份~50份丙烯酰胺、40份~150份2-丙烯酰胺基-2甲基丙磺酸钠及1份~15份乙二胺四乙酸二钠。
本实施方式中方中生川乌、生草乌为辛热燥烈之品,可用于经络之风湿、逐内里之寒邪,宣散气血;皮子药祛风散寒,活血消肿、解毒镇痛。独活、羌活祛风胜湿、散寒止痛,通利关节;白芷具有消肿止血、祛风止痛之功效;三棱、莪术活血化瘀,破血行气,消积止痛;细辛、干姜可温经散寒,祛风止痛;乳香、没药二药气香走窜而善行,气血并治,能活血散瘀,行气消肿止痛;红花、桃仁具有活血通经,散瘀止痛的功效;泽兰活血祛瘀,消肿止痛;川芎有活血行气、祛风止痛之功效,为“血中之气药”;当归补血活血,活血行瘀,为补血要药;二者合用具有行气活血、养血柔筋的作用。天南星燥湿化痰,祛风解痉,消肿止痛;黄柏清热燥湿,制约方中温阳药物辛温之性;石菖蒲味辛而芳香走窜,苦燥而善温化湿浊。
本实施方式凝胶基质选择丙烯酰胺、2-丙烯酰胺基-2甲基丙磺酸钠,并通过与乙二胺四乙酸二钠、羧甲纤维素钠的调配,实现缓释效果。
本实施方式的有益效果是:
本实施方式通过特定凝胶膏的选取及严格控制组分比例,使得凝胶膏起始时的突然释放被延缓,4h药物释放率小于25%,且10h的释放率小于80%,12h的释放率达到最大,释放率为98.9%,整体释放近似于线性,使药物以可控制的速度释放并被人体吸收,在血液中维持较为恒定的血药浓度,取得较好的治疗效果,风湿性关节炎患者治愈率达到98%,有效率达到100%。本实施方式的凝胶膏具有祛风散寒,活血消肿、解毒镇痛、活血祛瘀、消肿止痛、燥湿化痰、祛风解痉、行气活血、养血柔筋等功效。用于祛风散寒、舒筋活血、消肿止痛。
具体实施方式二:本实施方式与具体实施方式一不同的是:所述的辅料按质量份数由6000份乙醇、1份~50份冬青油、1份~50份冰片、1份~50份薄荷脑、100份~800份甘油、1份~50份蓖麻油、10份~100份羧甲纤维素钠、10份~50份丙烯酰胺、40份~150份2-丙烯酰胺基-2甲基丙磺酸钠、100份~500份山梨醇、10份~100份酒石酸、10份~100份高岭土、1份~30份甘羟铝,1份~15份乙二胺四乙酸二钠及600份~1500份纯化水组成。其它与具体实施方式一相同。
本实施方式中冰片、薄荷脑、冬青油芳香走窜,引药透皮,促进药物吸收。所述透皮吸收促进剂选择冬青油、冰片、薄荷脑;所述保湿助溶剂选择甘油、蓖麻油、山梨醇;
所述pH调节剂选择酒石酸;所述交联调节剂选择甘羟铝;所述赋形剂选择高岭土;所述溶剂选择纯化水。
具体实施方式三:本实施方式与具体实施方式一或二之一不同的是:祛风散寒、舒筋活血、消肿止痛缓释凝胶膏按质量份数由25份~50份没药、35份~70份川芎、35份~70份红花、25份~50份黄柏、100份~200份生川乌、100份~200份生草乌、60份~120份白芷、60份~120份当归、50份~100份干姜、25份~50份三棱、25份~50份莪术、25份~50份乳香、25份~50份独活、100份~200份天南星、35份~70份细辛、25份~50份羌活、100份~200份皮子药、50份~100份泽兰、35份~70份桃仁、60份~120份石菖蒲、6000份乙醇、1份~50份冬青油、1份~50份冰片、1份~50份薄荷脑、100份~800份甘油、1份~50份蓖麻油、10份~100份羧甲纤维素钠、10份~50份丙烯酰胺、40份~150份2-丙烯酰胺基-2甲基丙磺酸钠、100份~500份山梨醇、10份~100份酒石酸、10份~100份高岭土、1份~30份甘羟铝、1份~15份乙二胺四乙酸二钠及600份~1500份纯化水。其它与具体实施方式一或二相同。
具体实施方式四:本实施方式与具体实施方式一至三之一不同的是:所述的乙醇的质量百分数为90%。其它与具体实施方式一或二相同。
具体实施方式五:本实施方式一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,它是按以下步骤进行的:
一、将药剂依次投入提取罐中,加入乙醇,回流提取3h~5h,提取液滤至贮药罐内,再向提取罐中加入乙醇,回流提取3h~5h,合并提取液,回收乙醇,浓缩提取液至在温度60℃~80℃的相对密度为1.20~1.30,得到浸膏浓缩液;
二、将浸膏浓缩液、冬青油、冰片、薄荷脑及蓖麻油混合均匀,得到配方一;
三、将第一份丙烯酰胺、第一份2-丙烯酰胺基-2甲基丙磺酸钠、第一份羧甲纤维素钠及第一份甘油混合均匀,得到配方二;
四、向山梨醇中加入纯化水,得到山梨醇水溶液,将高岭土与山梨醇水溶液混合均匀,得到配方三;
五、以纯化水为配方四;
六、将第二份丙烯酰胺、第二份2-丙烯酰胺基-2甲基丙磺酸钠、第二份羧甲纤维素钠、第二份甘油、甘羟铝及乙二胺四乙酸二钠混合均匀,得到配方五;
七、以酒石酸为配方六;
八、将配方一与配方二加入混合罐中混合,再依次加入配方三、配方四、配方五及配方六混合,然后静置并再混合,得到膏体;
九、将膏体转移到涂布切割机上,以医用无纺布为背衬层、以硅塑纸为覆盖膜,然后涂布切割,切割后静置,经质检包装后,即得祛风散寒、舒筋活血、消肿止痛缓释凝胶膏。
具体实施方式六:本实施方式与具体实施方式一至五之一或不同的是:步骤一中所述的乙醇的质量百分数为90%。其它与具体实施方式一至五相同。
具体实施方式七:本实施方式与具体实施方式一至六之一不同的是:步骤三中所述的第一份丙烯酰胺与步骤六中所述的第二份丙烯酰胺的体积比为1:(1~3);步骤三中所述的第一份2-丙烯酰胺基-2甲基丙磺酸钠与步骤六中所述的第二份2-丙烯酰胺基-2甲基丙磺酸钠的体积比为1:(1~3);步骤三中所述的第一份羧甲纤维素钠与步骤六中所述的第二份羧甲纤维素钠的体积比为1:(1~3);步骤三中所述的第一份甘油与步骤六中所述的甘油的体积比为1:(1~3)。其它与具体实施方式一至六相同。
具体实施方式八:本实施方式与具体实施方式一至七之一不同的是:步骤四中向山梨醇中加入纯化水,得到质量百分数为70%~80%的山梨醇水溶液。其它与具体实施方式一至七相同。
具体实施方式九:本实施方式与具体实施方式一至八之一不同的是:步骤八中将配方一与配方二加入混合罐中,混合20s~40s,再加入配方三,混合20s~40s,再加入配方四,混合20s~40s,再加入配方五,混合100s~140s,最后加入配方六,混合160s~200s,然后静置220s~260s,再混合160s~200s。其它与具体实施方式一至八相同。
具体实施方式十:本实施方式与具体实施方式一至九之一不同的是:步骤九中切割后静置24h。其它与具体实施方式一至九相同。
采用以下实施例验证本发明的有益效果:
实施例一:
一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏,按质量份数由25份没药、35份川芎、35份红花、25份黄柏、100份生川乌、100份生草乌、60份白芷、60份当归、50份干姜、25份三棱、25份莪术、25份乳香、25份独活、100份天南星、35份细辛、25份羌活、100份皮子药、50份泽兰、35份桃仁、60份石菖蒲、6000份乙醇、10份冬青油、10份冰片、10份薄荷脑、400份甘油、10份蓖麻油、40份羧甲纤维素钠、30份丙烯酰胺、100份2-丙烯酰胺基-2甲基丙磺酸钠、200份山梨醇、40份酒石酸、45份高岭土、5份甘羟铝、10份乙二胺四乙酸二钠及650份纯化水;所述的乙醇的质量百分数为90%;
一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,它是按以下步骤进行的:
一、将25份没药、35份川芎、35份红花、25份黄柏、100份生川乌、100份生草乌、60份白芷、60份当归、50份干姜、25份三棱、25份莪术、25份乳香、25份独活、100份天南星、35份细辛、25份羌活、100份皮子药、50份泽兰、35份桃仁及60份石菖蒲净选合格后,依次投入提取罐中,加入3000份乙醇,回流提取4h,提取液滤至贮药罐内,再向提取罐中加入3000份乙醇,回流提取4h,合并提取液,回收乙醇,浓缩提取液至在温度60℃~80℃的相对密度为1.20~1.30,得到浸膏浓缩液;
二、将浸膏浓缩液、10份冬青油、10份冰片、10份薄荷脑及10份蓖麻油混合均匀,得到配方一;
三、将15份丙烯酰胺、50份2-丙烯酰胺基-2甲基丙磺酸钠、20份羧甲纤维素钠及200份甘油混合均匀,得到配方二;
四、向200份山梨醇中加入纯化水,得到质量百分数为75%的山梨醇水溶液,将45份高岭土与山梨醇水溶液混合均匀,得到配方三;
五、以650份纯化水为配方四;
六、将15份丙烯酰胺、50份2-丙烯酰胺基-2甲基丙磺酸钠、20份羧甲纤维素钠、200份甘油、5份甘羟铝及10份乙二胺四乙酸二钠混合均匀,得到配方五;
七、以40份酒石酸为配方六;
八、将配方一与配方二加入混合罐中,混合30s,再加入配方三,混合30s,再加入配方四,混合30s,再加入配方五,混合120s,最后加入配方六,混合180s,然后静置240s,并再混合180s,得到膏体;
九、将膏体转移到涂布切割机上,以医用无纺布为背衬层、以硅塑纸为覆盖膜,然后涂布切割,切割后静置24h,经质检包装后,即得祛风散寒、舒筋活血、消肿止痛缓释凝胶膏。
对比实验一:本对比实验与实施例一不同的是:取消30份丙烯酰胺的加入,将2-丙烯酰胺基-2甲基丙磺酸钠的用量改为130份。其它与实施例一相同。
对比实验二:本对比实验与实施例一不同的是:取消100份2-丙烯酰胺基-2甲基丙磺酸钠的加入,将丙烯酰胺的用量改为130份。其它与实施例一相同。
对比实验三:本对比实验与实施例一不同的是:将30份丙烯酰胺、100份2-丙烯酰胺基-2甲基丙磺酸钠替换为30份明胶、100份聚乙烯醇。其它与实施例一相同。
对比实验四:本对比实验与实施例一不同的是:取消10份乙二胺四乙酸二钠的加入,将羧甲纤维素钠的用量改为50份。其它与实施例一相同。
(1)过敏性研究
试验方法:取豚鼠15只,体重应为200g~300g,雌雄不限,用8%的硫化钠溶液退去豚鼠背部脊柱两侧的毛发,适应性饲养24h。将豚鼠随机平均分成3组,空白对照组、阳性对照组、实施例一凝胶膏组;其中,空白组是采用清水进行试验。
致敏接触试验:阳性对照组于豚鼠左侧脱毛区涂0.1%的2,4-二硝基氯苯溶液,用无纺布固定,6小时后去除捆绑将皮肤擦拭干净。空白组和实施例1凝胶膏组采用与阳性对照组同样方法对新的豚鼠进行致敏接触。第七和第十四天同样方法重复一次。
激发接触试验:末次致敏接触后14天,阳性对照组于豚鼠右侧脱毛区涂0.1%的2,4-二硝基氯苯溶液,用无纺布固定,6小时后去除捆绑立刻观察。空白组和凝胶膏组同样方法,分别于24、48小时再次观察皮肤致敏情况。
实验结果:阳性对照组中豚鼠皮肤出现红斑、水肿,持续72h以上,致敏率为100%。实施例1凝胶膏组和空白组均不引起豚鼠皮肤的红斑、水肿反应,对皮肤无致敏性,也未产生休克等全身过敏反应。结果见下表1:
表1皮肤过敏性试验结果
(2)急性毒性研究
试验方法:取家兔15只,体重应为2.0kg-2.5kg,雌雄不限。用8%的硫化钠溶液退去背部脊柱两侧的毛发,检查去毛皮肤是否受伤,适应性饲养24h。(家兔的体重平均为2.25kg,人的体重为70kg,人与家兔的体表面积比按照14.2计算,家兔的临床日剂量约为0.048g/kg,现给予剂量0.68g/kg,相当于约6.5倍剂量。)将家兔随机平均分成5组,空白对照组、凝胶膏生药量0.68g/kg完整皮肤组,凝胶膏生药量1.36g/kg完整皮肤组、凝胶膏生药量0.68g/kg破损皮肤组、凝胶膏生药量1.36g/kg破损皮肤组。破损皮肤组家兔备皮区用无菌针头作“#”字划痕至轻微渗血即可。空白对照组敷贴空白基质贴,正常剂量、高剂量组给予上述实施例1凝胶贴膏样品一贴和两贴,用无纺布固定给药部位。给药24小时后除去受试药物,于1、24、48、72小时到第14天,每日观察家兔的体重、饮食、外观、行为、分泌物、排泄物、皮肤、眼睛的变化及呼吸等中毒反应的起始时间、持续时间等,如有死亡动物,进行尸检和肉眼观察,及时进行病理解剖。
实验结果:在试验观察期内完整皮肤正常药物组、完整皮肤高剂量组以及空白对照组和破损皮肤正常剂量组的家兔行为无改变、饮食正常,毛发色泽无变化,口腔、眼、耳、鼻无分泌物,排泄物正常、无死亡。破损皮肤高剂量组24h后皮肤划痕处红肿,至14天时,红肿消失。与空白对照组比较,各组间动物体质增长差异无统计学意义。结果显示,本实施例的凝胶膏贴膏剂对家兔皮肤外用无明显急性毒性。给药前后变化见下表2:
表2家兔急毒实验结果
(3)舒适度研究
受试人群:100名患者,男性50例、女性50例。其中,30-40岁15人,40-50岁63人,50岁以上22人。
方法:以实施例一凝胶膏为样品,敷贴部位:肩部、腰部、肘部皮肤。皮肤清洁后,连续敷贴24小时,记录主观感受。
实验结果:试验结果中有两例受试者贴膏出现脱落,原因是粘贴于肘关节处,所有受试者贴敷后均无过敏反应,无膏体残留,无剥掉体毛等不适发生,敷贴后均不影响日常生活。敷贴后的个人感觉略有不同,与个人皮肤敏感度等有关,属于正常现象。结果见下表3:
表3凝胶膏敷贴舒适度结果
(4)释放度测定:
取小鼠腹部皮肤,将凝胶膏贴于小鼠腹部皮肤上,然后采用Franz透皮扩散仪,试验温度控制于37±0.5℃,在转速为100r/min的条件下,利用高效液相色谱仪测定,对生川乌进行累积释放。结果见下表4:
表4
组别 | 0.5h | 1h | 2h | 4h | 6h | 8h | 10 | 12h |
实施例一 | 6.3% | 10.5% | 15.6% | 21.3% | 35.7% | 59.1% | 75.6% | 98.9% |
对比实验一 | 33.6% | 42.9% | 60.6% | 75.6% | 91.9% | 92.4% | 93.1% | 93.4% |
对比实验二 | 15.2% | 28.4% | 36.3% | 50.9% | 80.8% | 94.3% | 95.1% | 95.7% |
对比实验三 | 43.1% | 60.4% | 82.7% | 91.4% | 92.1% | 93.3% | 93.5% | 93.7% |
对比实验四 | 13.5% | 26.9% | 31.3% | 49.5% | 75.4% | 95.1% | 95.5% | 96.1% |
实验结果:羧甲纤维素钠、丙烯酰胺、2-丙烯酰胺基-2甲基丙磺酸钠及乙二胺四乙酸二钠的配合,使得起始时的突然释放被延缓,4h药物释放率仅为21.3%,使药物以可控制的速度释放并为人体吸收,在血液中维持较为恒定的血药浓度,取得较好的治疗效果,12h后的最大释放率可达到98.9%。
(5)临床疗效:
受试人群:选择志愿者250名,均患有风湿性关节炎患者,年龄最小者24岁,年龄最大者59岁;病程1年~11年,临床表现为关节疼痛、肿胀、活动障碍、关节畸形,随机分为5组,每组50例。
使用方法:以实施例一及对比实验一至四制备的凝胶膏为样品,敷贴于病灶部位,每天一贴,使用5天为一个疗程。
评定标准:
治愈:使用1个疗程后,关节疼痛、肿胀消失,活动障碍及关节畸形明显好转;
有效:使用1个疗程后,关节疼痛、肿胀减轻,活动障碍及关节畸形部分逐步好转;
无效:使用1个疗程后,关节疼痛、肿胀、活动障碍、关节畸形无任何改善。
治疗评定结果:
使用实施例一制备的凝胶膏50例风湿性关节炎患者,使用1个疗程后,治愈49例,有效1例,无效0例。对治愈和有效患者进行后续观察,治愈患者使用3个疗程后,基本或全部恢复劳动能力,且连续观察36个月以上,不再复发。有效患者使用3个疗程后,症状现象明显降低,连续观察24个月不再发展。
使用对比实验一制备的凝胶膏50例风湿性关节炎患者,使用1个疗程后,治愈18例,有效22例,无效10例。对治愈和有效患者进行后续观察,治愈患者及有效患者使用3个疗程后,症状现象进一步降低,但连续观察4个月到10个月50%以上患者复发。
使用对比实验二制备的凝胶膏50例风湿性关节炎患者,使用1个疗程后,治愈21例,有效22例,无效7例。对治愈和有效患者进行后续观察,治愈患者及有效患者使用3个疗程后,症状现象进一步降低,但连续观察6个月到12个月50%以上患者复发。
使用对比实验三制备的凝胶膏50例风湿性关节炎患者,使用1个疗程后,治愈13例,有效25例,无效12例。对治愈和有效患者进行后续观察,治愈患者及有效患者使用3个疗程后,症状现象进一步降低,但连续观察2个月左右50%以上患者复发。
使用对比实验四制备的凝胶膏50例风湿性关节炎患者,使用1个疗程后,治愈28例,有效17例,无效5例。对治愈和有效患者进行后续观察,治愈患者及有效患者使用3个疗程后,症状现象进一步降低,但连续观察8个月到12个月50%以上患者复发。
Claims (8)
1.一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏,其特征在于它由药剂和辅料组成;
所述的药剂按质量份数由25份~50份没药、35份~70份川芎、35份~70份红花、25份~50份黄柏、100份~200份生川乌、100份~200份生草乌、60份~120份白芷、60份~120份当归、50份~100份干姜、25份~50份三棱、25份~50份莪术、25份~50份乳香、25份~50份独活、100份~200份天南星、35份~70份细辛、25份~50份羌活、100份~200份皮子药、50份~100份泽兰、35份~70份桃仁及60份~120份石菖蒲组成;
所述的辅料按质量份数由6000份乙醇、1份~50份冬青油、1份~50份冰片、1份~50份薄荷脑、100份~800份甘油、1份~50份蓖麻油、10份~100份羧甲纤维素钠、10份~50份丙烯酰胺、40份~150份2-丙烯酰胺基-2甲基丙磺酸钠、100份~500份山梨醇、10份~100份酒石酸、10份~100份高岭土、1份~30份甘羟铝,1份~15份乙二胺四乙酸二钠及600份~1500份纯化水组成。
2.根据权利要求1所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏,其特征在于所述的乙醇的质量百分数为90%。
3.如权利要求1所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,其特征在于它是按以下步骤进行的:
一、将药剂依次投入提取罐中,加入乙醇,回流提取3h~5h,提取液滤至贮药罐内,再向提取罐中加入乙醇,回流提取3h~5h,合并提取液,回收乙醇,浓缩提取液至在温度60℃~80℃的相对密度为1.20~1.30,得到浸膏浓缩液;
二、将浸膏浓缩液、冬青油、冰片、薄荷脑及蓖麻油混合均匀,得到配方一;
三、将第一份丙烯酰胺、第一份2-丙烯酰胺基-2甲基丙磺酸钠、第一份羧甲纤维素钠及第一份甘油混合均匀,得到配方二;
四、向山梨醇中加入纯化水,得到山梨醇水溶液,将高岭土与山梨醇水溶液混合均匀,得到配方三;
五、以纯化水为配方四;
六、将第二份丙烯酰胺、第二份2-丙烯酰胺基-2甲基丙磺酸钠、第二份羧甲纤维素钠、第二份甘油、甘羟铝及乙二胺四乙酸二钠混合均匀,得到配方五;
七、以酒石酸为配方六;
八、将配方一与配方二加入混合罐中混合,再依次加入配方三、配方四、配方五及配方六混合,然后静置并再混合,得到膏体;
九、将膏体转移到涂布切割机上,以医用无纺布为背衬层、以硅塑纸为覆盖膜,然后涂布切割,切割后静置,经质检包装后,即得祛风散寒、舒筋活血、消肿止痛缓释凝胶膏。
4.根据权利要求3所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,其特征在于步骤一中所述的乙醇的质量百分数为90%。
5.根据权利要求3所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,其特征在于步骤三中所述的第一份丙烯酰胺与步骤六中所述的第二份丙烯酰胺的体积比为1:(1~3);步骤三中所述的第一份2-丙烯酰胺基-2甲基丙磺酸钠与步骤六中所述的第二份2-丙烯酰胺基-2甲基丙磺酸钠的体积比为1:(1~3);步骤三中所述的第一份羧甲纤维素钠与步骤六中所述的第二份羧甲纤维素钠的体积比为1:(1~3);步骤三中所述的第一份甘油与步骤六中所述的甘油的体积比为1:(1~3)。
6.根据权利要求3所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,其特征在于步骤四中向山梨醇中加入纯化水,得到质量百分数为70%~80%的山梨醇水溶液。
7.根据权利要求3所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,其特征在于步骤八中将配方一与配方二加入混合罐中,混合20s~40s,再加入配方三,混合20s~40s,再加入配方四,混合20s~40s,再加入配方五,混合100s~140s,最后加入配方六,混合160s~200s,然后静置220s~260s,再混合160s~200s。
8.根据权利要求3所述的一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏的制备方法,其特征在于步骤九中切割后静置24h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211392938.3A CN116173168B (zh) | 2022-11-08 | 2022-11-08 | 一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211392938.3A CN116173168B (zh) | 2022-11-08 | 2022-11-08 | 一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116173168A CN116173168A (zh) | 2023-05-30 |
CN116173168B true CN116173168B (zh) | 2024-03-29 |
Family
ID=86439029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211392938.3A Active CN116173168B (zh) | 2022-11-08 | 2022-11-08 | 一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116173168B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1269206A (zh) * | 1999-04-06 | 2000-10-11 | 哈尔滨太阳岛制药厂 | 风湿骨痛贴膏巴布剂制作方法 |
CN104277174A (zh) * | 2013-07-09 | 2015-01-14 | 中国石油化工股份有限公司 | 聚丙烯酰胺纳米微球体系及其制备方法 |
CN106692934A (zh) * | 2017-01-18 | 2017-05-24 | 韩爱民 | 镇痛黑膏药及其制备方法 |
CN110743000A (zh) * | 2019-12-05 | 2020-02-04 | 王永明 | 一种用于穴位贴敷湿敷贴的中药组合物及其制备方法和使用方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
-
2022
- 2022-11-08 CN CN202211392938.3A patent/CN116173168B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1269206A (zh) * | 1999-04-06 | 2000-10-11 | 哈尔滨太阳岛制药厂 | 风湿骨痛贴膏巴布剂制作方法 |
CN104277174A (zh) * | 2013-07-09 | 2015-01-14 | 中国石油化工股份有限公司 | 聚丙烯酰胺纳米微球体系及其制备方法 |
CN106692934A (zh) * | 2017-01-18 | 2017-05-24 | 韩爱民 | 镇痛黑膏药及其制备方法 |
CN110743000A (zh) * | 2019-12-05 | 2020-02-04 | 王永明 | 一种用于穴位贴敷湿敷贴的中药组合物及其制备方法和使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN116173168A (zh) | 2023-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169928B (zh) | 治疗痛经的外用中药组合物及其制备方法和应用 | |
CN110652558A (zh) | 一种治疗化疗性静脉炎的中药水凝胶贴剂及其制备方法 | |
CN102579583A (zh) | 治疗筋伤的外用贴剂 | |
CN106822326A (zh) | 新型中药贴剂颈痛贴膏及其制备方法 | |
CN101979011A (zh) | 治疗颈椎病的中药经皮凝胶膏剂及其制备方法 | |
CN116173168B (zh) | 一种祛风散寒、舒筋活血、消肿止痛缓释凝胶膏及其制备方法 | |
CN1274342C (zh) | 治疗痛风的中药外用制剂及其制备方法 | |
CN101703667B (zh) | 一种竭红跌打药剂及其制备方法 | |
CN115227679A (zh) | 麝香镇痛凝胶贴膏及其制备方法 | |
CN109908112B (zh) | 一种不过敏的橡胶膏贴膏及其制备方法 | |
CN111759905A (zh) | 一种治疗骨关节炎的巴布剂及其制备方法 | |
CN102302616A (zh) | 治疗膝骨性关节炎巴布剂及其制备方法 | |
CN113181240A (zh) | 构树根皮在制备治疗特应性皮炎的药物上的应用 | |
CN110403988B (zh) | 一种具有外用活血化瘀作用的中药软膏及其制备方法 | |
CN110123976A (zh) | 一种治疗痔疮用傣药涂抹膏及其制备方法 | |
CN114886981B (zh) | 中药组合物及其在制备颈肩腰腿痛药中的应用 | |
CN116036225B (zh) | 一种天然来源的治疗关节炎的外用药物组合物 | |
CN114601787B (zh) | 一种复合制剂、制备方法及其应用 | |
CN114377116B (zh) | 一种含水蛭素的敷料及其制备方法 | |
CN108310314A (zh) | 一种用于止痛的植物提取物组合物 | |
CN114028441B (zh) | 一种参皇软膏及其制备方法和应用 | |
CN109846861B (zh) | 一种蒙药外用贴膏及其制备方法 | |
CN115721674B (zh) | 一种创口护理用组合物及其应用 | |
CN108434299B (zh) | 用于治疗肩周炎的药物组合物及其制备方法与喷雾剂 | |
CN107296850B (zh) | 一种治疗犬疮疡的中药凝胶剂的产品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |